<DOC>
	<DOCNO>NCT02114502</DOCNO>
	<brief_summary>The goal clinical research study learn carfilzomib vorinostat combine gemcitabine , busulfan , melphalan stem cell transplant help control multiple myeloma ( MM ) . Researchers also want learn safety effectiveness combination .</brief_summary>
	<brief_title>Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant Myeloma</brief_title>
	<detailed_description>Busulfan Test Dose : Participant receive test dose busulfan vein 60 minute . This low-level test dose busulfan check level busulfan participant 's blood change time . This information use decide next dose need reach target blood level match participant 's body size . Participant likely receive outpatient week admit hospital . If give participant outpatient , admitted hospital Day -11 ( 11 day participant 's stem cell return body ) test dose give Day -10 . About 11 sample blood ( 1 teaspoon time ) drawn pharmacokinetic ( PK ) test busulfan . PK test measure amount study drug body different time point help study doctor decide participant 's dose busulfan study . These blood sample draw various timepoints participant receives busulfan next 11 hour . The blood sample repeat first day high-dose busulfan treatment ( Day -8 ) . A temporary heparin lock line place participant 's vein lower number needle stick need draws . If possible PK test perform technical scheduling reason , participant receive standard fix dose busulfan . If participant receives busulfan test dose outpatient : On Days -12 , -11 , -10 , participant receive palifermin vein 30 second day help decrease risk side effect mouth throat . Participant admit hospital Day -9 . If participant receives busulfan test dose inpatient : On Days -14 , -13 , -12 , participant receive palifermin vein 30 second day help decrease risk side effect mouth throat . Participant admit hospital Day -11 . Study Drug Administration ( participant ) : With stem cell transplant , day participant receive stem cell call minus day . The day participant receive stem cell call Day 0 . The day participant receive stem cell call plus day . Beginning Day -9 , participant swish liquid caphosol glutamine mouth 4 time day , 2 minute time . Participant swish liquid every day leave hospital . These drug use help decrease risk side effect mouth throat . On Day -9 Day -2 , participant receive dexamethasone 2 time day vein 10 minute . On Day -8 Day -2 , participant take vorinostat mouth , food . On Day -8 , participant receive gemcitabine vein 4 hour . On Days -8 , -7 , -6 , -5 , participant receive busulfan vein 3 hour . On Days -7 -6 , participant receive carfilzomib vein 2-10 minute . On Day -3 , participant receive gemcitabine vein 4 hour melphalan vein 30 minute . On Day -2 , participant receive carfilzomib vein 2-10 minute melphalan vein 30 minute . On Day -1 , participant receive carfilzomib vein 2-10 minute . On Day 0 , participant receive stem cell vein 30-60 minute . Participant receive 3 dos palifermin vein 15-30 second Days 0 , +1 +2 . As part standard care , participant receive G-CSF ( filgrastim ) injection skin 1 time day start Day +5 blood cell level return normal . Study Tests : About 1 month , 100 day , 6 month , 1 year , every 3-6 month least 2 year transplant : - Participant physical exam . - Blood ( 4 tablespoon ) draw routine test , learn transplant take , check status disease . About 100 day transplant , participant bone marrow biopsy aspiration check status disease . To collect bone marrow biopsy aspirate , area hip site numb anesthetic , small amount bone bone marrow withdrawn large needle . This repeat year earlier , participant 's doctor think need . Once year , participant x-rays bone body check status disease . The study staff also stay contact participant 's local doctor find disease come back check . Length Treatment : As part standard care , participant remain hospital 3-4 week transplant . After participant release hospital , continue outpatient Houston area monitor infection transplant-related complication . Participant take study 2 year transplant . Participant may take study early disease get bad , intolerable side effect occur , unable follow study direction . If reason participant want leave study early , must talk study doctor . It may life-threatening leave study participant start receive study drug receive stem cell transplant blood cell count dangerously low . This investigational study . Carfilzomib melphalan FDA approve treatment MM . Vorinostat FDA approve treatment cutaneous lymphoma . Busulfan FDA approve treatment leukemia . Gemcitabine FDA approve treatment lymphoma , breast cancer , lung cancer . The use study drug combination investigational . The study doctor explain study drug design work . Up 75 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<criteria>1 . Age 18 65 year 2 . Refractory relapse myeloma , define one following : 1 . Patients myeloma treat firstline therapy include lenalidomide , bortezomib thalidomide , one following : . Less partial response firstline therapy . b. Relapse 1st line therapy . 2 . Highrisk disease , define del ( 13q ) conventional cytogenetics , del ( 17p ) , ( 4 ; 14 ) , ( 14 ; 16 ) , ( 14 ; 20 ) 1q+ FISH . 3 . Relapse prior autologous stemcell transplantation ( ASCT ) . 4 . Plasma cell leukemia . 5 . Plasmablastic lymphoma . 6 . Soft tissue plasmacytoma . 3 . Adequate renal function , define serum creatinine &lt; /=1.8 mg/dL and/or estimate serum creatinine clearance &gt; /=50 ml/min . 4 . Adequate hepatic function , define serum glutamate oxaloacetate ( SGOT ) and/or serum glutamicpyruvic transaminase ( SGPT ) &lt; /=3 x upper limit normal ; serum bilirubin alkaline phosphatase &lt; /=2 x upper limit normal , unless prove due disease involvement . 5 . Adequate pulmonary function FEV1 , FVC DLCO &gt; /=50 % expect corrected hemoglobin and/or volume . 6 . Adequate cardiac function leave ventricular ejection fraction &gt; /=40 % . No uncontrolled arrhythmias symptomatic cardiac disease . 7 . Zubrod performance status &lt; 2 . 8 . Negative Beta HCG text woman childbearing potential , define postmenopausal 12 month previous surgical sterilization . 1 . Patients grade &gt; /= 3 nonhematologic toxicity previous therapy resolve &lt; /= grade 1 . 2 . Prior whole brain irradiation . 3 . Active hepatitis B , either active carrier ( HBsAg + ) viremic ( HBV DNA &gt; /=10,000 copies/mL , &gt; /= 2,000 IU/mL ) . 4 . Evidence either cirrhosis stage 34 liver fibrosis patient chronic hepatitis C positive hepatitis C serology . 5 . Active infection require parenteral antibiotic . 6 . HIV infection , unless patient receive effective antiretroviral therapy undetectable viral load normal CD4 count . 7 . Patients receive radiation therapy head neck ( exclude eye ) , internal organ chest , abdomen pelvis month prior enrollment . 8 . Autologous stemcell transplant previous six month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>MM</keyword>
	<keyword>Refractory</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Stem Cell Transplant</keyword>
	<keyword>SCT</keyword>
	<keyword>Carfilzomib</keyword>
	<keyword>SAHA</keyword>
	<keyword>Vorinostat</keyword>
	<keyword>Suberoylanilide Hydroxamic Acid</keyword>
	<keyword>MSK-390</keyword>
	<keyword>Zolinza</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemcitabine Hydrochloride</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Palifermin</keyword>
	<keyword>Kepivance</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>Caphosol</keyword>
	<keyword>Glutamine</keyword>
	<keyword>Enterex</keyword>
	<keyword>Glutapak-10</keyword>
	<keyword>NutreStore</keyword>
	<keyword>Resource</keyword>
	<keyword>GlutaSolve</keyword>
	<keyword>Sympt-X G.I .</keyword>
	<keyword>Sympt-X</keyword>
	<keyword>Pyridoxine</keyword>
</DOC>